Clinical applications of the techniques employed in autonomic nervous system assessment;Le applicazioni cliniche delle metodiche di valutazione del sistema nervoso autonomo

Italian Heart Journal Supplement

Volumn 2, Issue 8, 2001, Pages 823-830

  Mancia, G ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Autonomic nervous system; Cardiovascular risk; Congestive heart failure; Diabetes; Hypertension; Myocardial infarction

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR RISK; DIABETES MELLITUS; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; REVIEW;

AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION;

EID: 0034762177     PISSN: 11294728     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Diabetic neuropathy: Pathogenesis and therapy
2. Sympathetic nervous system
3. Role of the sympathetic nervous system in human hypertension
4. Sympathetic activation in obese normotensive subjects
5. Adrenergic and reflex abnormalities in obesity-related hypertension
6. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
7. Baroreflex sensitivity and cardiovascular mortality in patients with mild to moderate congestive heart failure
8. Baroreflex sensitivity, clinical correlates and cardiovascular mortality among patients with a first myocardial infarction: A prospective study
9. Diabetic autonomic neuropathy and the heart
10. Evaluation of baroreceptor reflex by blood pressure monitoring in unanesthetized cats
11. Evaluation of the baroreceptor-heart rate reflex by 24-hour intra-arterial blood pressure monitoring in humans
12. Time and frequency domain estimates of spontaneous baroreflex sensitivity provide early detection of autonomic dysfunction in diabetes mellitus
13. Spectral analysis of heart rate variability in the assessment of autonomic diabetic neuropathy
14. Predictors of abnormal cardiovascular autonomic function measured by frequency domain analysis of heart rate variability and conventional tests in patients with type I diabetes
15. Diabetic neuropathy in NIDDM
16. Early diagnosis of diabetic autonomic neuropathy: Present and future approaches
17. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
18. Effect of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
19. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure
20. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)
21. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction
22. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality
23. Sympathetic mechanisms in heart failure. Pathophysiological and pharmacological implications
24. Assessment of autonomic regulation in chronic heart failure by heart rate spectral analysis
25. Heart rate spectral analysis, cardiac norepinephrine spillover, and muscle sympathetic nerve activity during human sympathetic nervous activation and failure
26. Comparison between reproducibility and sensitivity of muscle sympathetic nerve traffic and plasma noradrenaline in man
27. Long-term variability and reproducibility of resting human muscle nerve sympathetic activity at rest, as reassessed after a decade
28. Effects of amlodipine on sympathetic nerve traffic and baroreflex control of circulation in heart failure
29. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity
30. Overflow of catecholamine neurotransmitters to the circulation: Source, fate and functions
31. The assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover
32. Heart rate variability and cardiac failure
33. Heart rate variability in left ventricular dysfunction and heart failure: Effects and implications of drug treatment
34. How to assess sympathetic activity in humans
35. Arterial baroreflex in humans
36. Sympathoadrenergic overactivity and lipid metabolism
37. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension
38. Increased regional sympathetic nervous activity in human hypertension: Causes and consequences
39. Autonomic nervous system dysregulation in human hypertension
40. 1999 World Health Organization/International Society of Hypertension guidelines for the management of hypertension
41. ACE-inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease
42. Intracoronary angiotensin II potentiates coronary sympathetic vasoconstriction in humans
43. Modulation of sympathetic coronary vasoconstriction by cardiac renin-angiotensin system in human coronary heart disease
44. Effect of angiotensin-converting enzyme inhibition on cardiovascular regulation during sympathetic activation in sodium-replete patients with essential hypertension
45. Effect of chronic angiotensin-converting-enzyme inhibition on sympathetic nerve traffic and baroreflex control of circulation in essential hypertension
46. Effect of calcium antagonists on sympathetic activity
47. Regression of left ventricular hypertrophy in hypertension: Changing patterns with successive meta-analyses
48. Effects of antihypertensive therapy on hypertensive vascular disease
49. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension
50. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium-channel antagonist
51. The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls
52. Evaluating sympathetic and hemodynamic responses to mental stressors: Bankering or achievement?
53. Bjorn Folkow Award Lecture. The sympathetic nervous system in hypertension
54. Methodological problems in evaluation of cardiovascular effects of stress in humans
55. Variability of the haemodynamic responses to laboratory tests employed in the assessment of neural cardiovascular regulation in man
56. Comparison of the cardiovascular effects of different laboratory stressors and their relationship with blood pressure variability
57. The changing face of sympathetic overactivity in hypertension
58. Relevance of heart rate as a risk factor in hypertension
59. The physiological determinants and risk correlations of elevated heart rate
60. Dysautonomia and neurocardiogenic syncope
61. Autonomic function following myocardial infarction
62. Insights from the study of heart rate variability
63. Relation between heart rate variability early after acute myocardial infarction and long-term mortality
64. Early alterations of the baroreceptor control of heart rate in patients with acute myocardial infarction
65. Cardiopulmonary receptor and arterial baroreceptor reflexes after acute myocardial infarction
66. Baroreflex and non-baroreflex modulation of vagal cardiac control after myocardial infarction
67. Body weight reduction, sympathetic nerve traffic and arterial baroreflex in obese normotensive humans
68. Dissociation between muscle and skin sympathetic nerve activity in hypertension, obesity and congestive heart failure